Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CRDLBullishCorporate Developmentsnews

High materiality8/10

Cardiol Therapeutics Expands MAVERIC Enrollment; Mid-2027 Topline Outlook

Sep 23, 2026, 6:52 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Expansion to 150 patients could strengthen readout robustness and extend trial timeline; topline mid-2027 provides a clearer catalyst path while funding remains solid through Q1 2028, which can support upside if results are favorable.

AI summary

What happened, with direct paths to the underlying reporting

Cardiol Therapeutics reports MAVERIC enrollment at 110, with a recommended expansion to up to 150 patients to achieve robust efficacy data. A blinded review indicates fewer pericarditis recurrences than anticipated, supporting CardiolRx's potential. Topline readout is now slated for mid-2027, and the company maintains a cash runway into Q1 2028, reducing near-term funding risk while extending development optionality.

As of Sep 23, 2026, MAVERIC enrolled 110 patients. Enrollment target met ahead of guidance.
Steering Committee recommends expanding MAVERIC to up to 150 patients. Aim to preserve trial power.
Blinded review shows fewer recurrences than expected. No known practice changes explain the result.
Topline results now expected in mid-2027. Cash runway extends into Q1 2028.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.